Suneva Medical appoints Chadha vice president, regulatory affairs

Suneva Medical has appointed Deepak Chadha as vice president of regulatory affairs, the privately held aesthetics company announced.

“Deepak has been responsible for several global regulatory strategies that have led to the successful submission and approval of aesthetic and therapeutic products in the US and overseas,” Nicholas L. Teti Jr., chairman and chief executive officer of Suneva Medical, said in a press release. “He will help us meet our vision to become a standout in the aesthetics market.”

Chadha, who held regulatory affairs positions at companies including Kythera Biopharmaceuticals and Allergan Medical, will be responsible for developing and implementing Suneva’s regulatory strategies, according to the release. In his role as vice president, regulatory affairs at Kythera, Chadha led the development of injectable ATX-101, sodium deoxycholate, a synthetic bile salt used to treat submental fat, the release stated.

“I am optimistic that my role will help drive [Suneva Medical’s] growth strategy,” Chadha said in the release.